Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

OXYCODONE HCL

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N02A, N02AA) — coverage varies; not interchangeable

  • Hydromorphone (Hydromorph Contin): general benefit, Not a benefit
  • Morphine (M-Eslon): general benefit, Not a benefit
  • Acetylsalicylic acid + butalbital + caffeine + codeine (Fiorinal C1/4): not a benefit
  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, Not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, Not a benefit
  • Fentanyl transdermal system (Duragesic 12): limited Use 511, Limited Use 689, Not a benefit

2 more in the class list below

Oxy.IR · DIN 02231934 · 5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Supeudol; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg, 20 mg — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg For use when palliative patient cannot use combination oxycodone and acetaminophen. Standard Approval Duration: 12 months EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 314, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Oxy.IR · DIN 02231934 Manufacturer: Purdue Pharma; listing date 2009-01-30 Health Canada: Marketed since 2000-03-31 · brand OXY.IR · ATC N02AA05 OXYCODONE · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 5 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Oxy.IR: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51386 · Verify on the e-Formulary ↗ (DIN 02231934)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02231934). DIN 02231934: Oxy.IR Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808119; group id 409; item number 1009; lccId None; manufacturer id PFP Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02231934 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=51386
Interchangeable products
PMS-Oxycodone · DIN 02319977 · $0.2333 Supeudol · DIN 00789739 · $0.2333
Shortage status: resolved shortage (ended 2025-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02231934
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Oxycodone · DIN 02319977 · 5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Supeudol; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg, 20 mg — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg For use when palliative patient cannot use combination oxycodone and acetaminophen. Standard Approval Duration: 12 months EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 314, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
PMS-Oxycodone · DIN 02319977 Manufacturer: Pharmascience Inc.; listing date 2009-01-30 Health Canada: Marketed since 2008-12-03 · brand PMS-OXYCODONE · ATC N02AA05 OXYCODONE · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 5 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

PMS-Oxycodone: Formulary list price $0.2333/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2333 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80542 · Verify on the e-Formulary ↗ (DIN 02319977)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02319977). DIN 02319977: PMS-Oxycodone Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808119; group id 409; item number 1009; lccId None; manufacturer id PMS Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.2333; ministry $0.2333 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02319977 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80542
Interchangeable products
Oxy.IR · DIN 02231934 · not recorded Supeudol · DIN 00789739 · $0.2333
Shortage status: resolved shortage (ended 2021-12-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319977
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Supeudol · DIN 00789739 · 5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg For use when palliative patient cannot use combination oxycodone and acetaminophen. Standard Approval Duration: 12 months EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 314, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Supeudol · DIN 00789739 Manufacturer: Sandoz Canada Inc.; listing date 2010-04-23 Health Canada: Marketed since 2005-08-05 · brand SUPEUDOL 5 · ATC N02AA05 OXYCODONE · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 5 MG · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Supeudol: Formulary list price $0.2333/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2333 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10433 · Verify on the e-Formulary ↗ (DIN 00789739)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00789739). DIN 00789739: Supeudol Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808119; group id 409; item number 1009; lccId None; manufacturer id SDZ Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.2333; ministry $0.2333 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00789739 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10433
Interchangeable products
Oxy.IR · DIN 02231934 · not recorded PMS-Oxycodone · DIN 02319977 · $0.2333
Shortage status: resolved shortage (ended 2025-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00789739
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Oxy.IR · DIN 02240131 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Supeudol; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg, 20 mg — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg For use when palliative patient cannot use combination oxycodone and acetaminophen. Standard Approval Duration: 12 months EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 314, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Oxy.IR · DIN 02240131 Manufacturer: Purdue Pharma; listing date 2009-01-30 Health Canada: Marketed since 2000-03-31 · brand OXY.IR · ATC N02AA05 OXYCODONE · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 10 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Oxy.IR: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63645 · Verify on the e-Formulary ↗ (DIN 02240131)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02240131). DIN 02240131: Oxy.IR Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808120; group id 409; item number 1010; lccId None; manufacturer id PFP Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240131 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63645
Interchangeable products
PMS-Oxycodone · DIN 02319985 · $0.3451 Supeudol · DIN 00443948 · $0.3451
Shortage status: resolved shortage (ended 2024-11-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240131
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Oxycodone · DIN 02319985 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Supeudol; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg, 20 mg — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg For use when palliative patient cannot use combination oxycodone and acetaminophen. Standard Approval Duration: 12 months EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 314, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
PMS-Oxycodone · DIN 02319985 Manufacturer: Pharmascience Inc.; listing date 2009-01-30 Health Canada: Marketed since 2008-12-03 · brand PMS-OXYCODONE · ATC N02AA05 OXYCODONE · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 10 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

PMS-Oxycodone: Formulary list price $0.3451/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3451 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80543 · Verify on the e-Formulary ↗ (DIN 02319985)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02319985). DIN 02319985: PMS-Oxycodone Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808120; group id 409; item number 1010; lccId None; manufacturer id PMS Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3451; ministry $0.3451 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02319985 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80543
Interchangeable products
Oxy.IR · DIN 02240131 · not recorded Supeudol · DIN 00443948 · $0.3451
Shortage status: resolved shortage (ended 2021-12-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319985
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Supeudol · DIN 00443948 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg For use when palliative patient cannot use combination oxycodone and acetaminophen. Standard Approval Duration: 12 months EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 314, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Supeudol · DIN 00443948 Manufacturer: Sandoz Canada Inc.; listing date 2010-04-23 Health Canada: Marketed since 2005-08-05 · brand SUPEUDOL 10 · ATC N02AA05 OXYCODONE · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 10 MG · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Supeudol: Formulary list price $0.3451/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3451 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3996 · Verify on the e-Formulary ↗ (DIN 00443948)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00443948). DIN 00443948: Supeudol Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808120; group id 409; item number 1010; lccId None; manufacturer id SDZ Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.3451; ministry $0.3451 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00443948 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3996
Interchangeable products
Oxy.IR · DIN 02240131 · not recorded PMS-Oxycodone · DIN 02319985 · $0.3451
Shortage status: resolved shortage (ended 2025-05-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00443948
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Oxy.IR · DIN 02240132 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Supeudol; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg, 20 mg — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg For use when palliative patient cannot use combination oxycodone and acetaminophen. Standard Approval Duration: 12 months EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 314, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Oxy.IR · DIN 02240132 Manufacturer: Purdue Pharma; listing date 2008-10-01 Health Canada: Marketed since 2000-03-31 · brand OXY.IR · ATC N02AA05 OXYCODONE · form Tablet (immediate-release) · route Oral · ingredients OXYCODONE HYDROCHLORIDE 20 MG · company Purdue pharma · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Oxy.IR: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63646 · Verify on the e-Formulary ↗ (DIN 02240132)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02240132). DIN 02240132: Oxy.IR Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808121; group id 409; item number 1011; lccId None; manufacturer id PFP Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240132 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63646
Interchangeable products
PMS-Oxycodone · DIN 02319993 · $0.6001 Supeudol · DIN 02262983 · $0.6001
Shortage status: resolved shortage (ended 2023-02-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240132
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Oxycodone · DIN 02319993 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Supeudol; DOSAGE FORM/ STRENGTH: 5 mg, 10 mg, 20 mg — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg For use when palliative patient cannot use combination oxycodone and acetaminophen. Standard Approval Duration: 12 months EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 314, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
PMS-Oxycodone · DIN 02319993 Manufacturer: Pharmascience Inc.; listing date 2009-01-30 Health Canada: Marketed since 2008-12-03 · brand PMS-OXYCODONE · ATC N02AA05 OXYCODONE · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 20 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

PMS-Oxycodone: Formulary list price $0.6001/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6001 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80544 · Verify on the e-Formulary ↗ (DIN 02319993)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02319993). DIN 02319993: PMS-Oxycodone Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808121; group id 409; item number 1011; lccId None; manufacturer id PMS Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.6001; ministry $0.6001 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02319993 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80544
Interchangeable products
Oxy.IR · DIN 02240132 · not recorded Supeudol · DIN 02262983 · $0.6001
Shortage status: resolved shortage (ended 2025-04-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02319993
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Supeudol · DIN 02262983 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg For use when palliative patient cannot use combination oxycodone and acetaminophen. Standard Approval Duration: 12 months EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 474, record 314, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Supeudol · DIN 02262983 Manufacturer: Sandoz Canada Inc.; listing date 2008-10-01 Health Canada: Marketed since 2024-10-04 · brand SUPEUDOL 20 · ATC N02AA05 OXYCODONE · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 20 MG · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Supeudol: Formulary list price $0.6001/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6001 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74839 · Verify on the e-Formulary ↗ (DIN 02262983)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02262983). DIN 02262983: Supeudol Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 280808121; group id 409; item number 1011; lccId None; manufacturer id SDZ Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.6001; ministry $0.6001 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02262983 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74839
Interchangeable products
Oxy.IR · DIN 02240132 · not recorded PMS-Oxycodone · DIN 02319993 · $0.6001
Shortage status: resolved shortage (ended 2025-08-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02262983
Shortage record checked 2026-09-13T08:10:21.292534+00:00

OXYCODONE HCL & ACETAMINOPHEN

4 general benefit · 1 not a benefit

Other products in the same Health Canada class (N02A, N02AA) — coverage varies; not interchangeable

  • Hydromorphone (Hydromorph Contin): general benefit, Not a benefit
  • Morphine (M-Eslon): general benefit, Not a benefit
  • Acetylsalicylic acid + butalbital + caffeine + codeine (Fiorinal C1/4): not a benefit
  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, Not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, Not a benefit
  • Fentanyl transdermal system (Duragesic 12): limited Use 511, Limited Use 689, Not a benefit

2 more in the class list below

Apo-Oxycodone/Acet · DIN 02324628 · 5mg & 325mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Oxycodone/Acet · DIN 02324628 Manufacturer: Apotex Inc.; listing date 2009-09-30 Health Canada: Marketed since 2009-05-22 · brand APO-OXYCODONE/ACET · ATC N02AJ17 OXYCODONE AND PARACETAMOL, N02AJ17 OXYCODONE AND PARACETAMOL · form Tablet · route Oral · ingredients ACETAMINOPHEN 325 MG, OXYCODONE HYDROCHLORIDE 5 MG · company Apotex inc · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Apo-Oxycodone/Acet: Formulary list price $0.1285/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1285 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81005 · Verify on the e-Formulary ↗ (DIN 02324628)

Source record
DIN 02324628: Apo-Oxycodone/Acet Raw flags: sec3=Y Item: 280808064; group id 410; item number 1012; lccId None; manufacturer id APX Source form: Tab; strength: 5mg & 325mg Recorded listing: General benefit Source prices (unrounded): $0.1285; ministry $0.1285 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02324628 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81005
Interchangeable products
Endocet · DIN 01916548 · $0.1285 Percocet · DIN 01916475 · not recorded Sandoz Oxycodone/Acetaminophen · DIN 02307898 · $0.1285 Teva-Oxycocet · DIN 00608165 · $0.1285
Shortage status: shortage reported ended 2026-06-18 (report last updated 2026-06-18); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02324628
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Oxycocet · DIN 00608165 · 5mg & 325mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Oxycocet · DIN 00608165 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2017-07-07 · brand TEVA-OXYCOCET · ATC N02AJ17 OXYCODONE AND PARACETAMOL, N02AJ17 OXYCODONE AND PARACETAMOL · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 5 MG, ACETAMINOPHEN 325 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Teva-Oxycocet: Formulary list price $0.1285/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1285 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5778 · Verify on the e-Formulary ↗ (DIN 00608165)

Source record
DIN 00608165: Teva-Oxycocet Raw flags: sec3=Y Item: 280808064; group id 410; item number 1012; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg & 325mg Recorded listing: General benefit Source prices (unrounded): $0.1285; ministry $0.1285 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00608165 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5778
Interchangeable products
Apo-Oxycodone/Acet · DIN 02324628 · $0.1285 Endocet · DIN 01916548 · $0.1285 Percocet · DIN 01916475 · not recorded Sandoz Oxycodone/Acetaminophen · DIN 02307898 · $0.1285
Shortage status: active shortage (reported 2025-06-18, estimated to end 2026-10-01, last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00608165
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Oxycodone/Acetaminophen · DIN 02307898 · 5mg & 325mg · tablet

General benefitDormant since 2025-07-28 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Oxycodone/Acetaminophen · DIN 02307898 Manufacturer: Sandoz Canada Inc.; listing date 2008-10-01 Health Canada: Dormant since 2025-07-28 · brand SANDOZ OXYCODONE/ACETAMINOPHEN · ATC N02AJ17 OXYCODONE AND PARACETAMOL, N02AJ17 OXYCODONE AND PARACETAMOL · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 5 MG, ACETAMINOPHEN 325 MG · company Sandoz canada incorporated · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Sandoz Oxycodone/Acetaminophen: Formulary list price $0.1285/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1285 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79356 · Verify on the e-Formulary ↗ (DIN 02307898)

Source record
DIN 02307898: Sandoz Oxycodone/Acetaminophen Raw flags: sec3=Y Item: 280808064; group id 410; item number 1012; lccId None; manufacturer id SDZ Source form: Tab; strength: 5mg & 325mg Recorded listing: General benefit Source prices (unrounded): $0.1285; ministry $0.1285 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02307898 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79356
Interchangeable products
Apo-Oxycodone/Acet · DIN 02324628 · $0.1285 Endocet · DIN 01916548 · $0.1285 Percocet · DIN 01916475 · not recorded Teva-Oxycocet · DIN 00608165 · $0.1285
Shortage status: discontinued (2024-05-01, reported by SANDOZ CANADA INCORPORATED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02307898
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-28 — choose a marketed DIN from the same-category list.

Endocet · DIN 01916548 · 5mg & 325mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2017-10-13 — choose a marketed DIN from the same-category list.Discontinued 2017-10-13 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2017-10-13 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2017-10-13 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Endocet · DIN 01916548 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01 Health Canada: Cancelled post market since 2017-10-13 · brand ENDOCET · ATC N02AJ17 OXYCODONE AND PARACETAMOL, N02AJ17 OXYCODONE AND PARACETAMOL · form Tablet · route Oral · ingredients ACETAMINOPHEN 325 MG, OXYCODONE HYDROCHLORIDE 5 MG · company Bristol-myers squibb canada · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Endocet: Formulary list price $0.1285/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1285 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17235 · Verify on the e-Formulary ↗ (DIN 01916548)

Source record
DIN 01916548: Endocet Raw flags: sec3=Y Item: 280808064; group id 410; item number 1012; lccId None; manufacturer id BQU Source form: Tab; strength: 5mg & 325mg Recorded listing: General benefit Source prices (unrounded): $0.1285; ministry $0.1285 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916548 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17235
Interchangeable products
Apo-Oxycodone/Acet · DIN 02324628 · $0.1285 Percocet · DIN 01916475 · not recorded Sandoz Oxycodone/Acetaminophen · DIN 02307898 · $0.1285 Teva-Oxycocet · DIN 00608165 · $0.1285
Shortage status: discontinued (2017-09-21, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916548
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-10-13 — choose a marketed DIN from the same-category list.

Percocet · DIN 01916475 · 5mg & 325mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-23 — choose a marketed DIN from the same-category list.Discontinued 2017-08-23 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-08-23 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-08-23 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Percocet · DIN 01916475 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2008-12-23 Health Canada: Cancelled post market since 2017-08-23 · brand PERCOCET · ATC N02AJ17 OXYCODONE AND PARACETAMOL, N02AJ17 OXYCODONE AND PARACETAMOL · form Tablet · route Oral · ingredients ACETAMINOPHEN 325 MG, OXYCODONE HYDROCHLORIDE 5 MG · company Bristol-myers squibb canada · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Percocet: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15514 · Verify on the e-Formulary ↗ (DIN 01916475)

Source record
DIN 01916475: Percocet Raw flags: notABenefit=Y, sec3=Y Item: 280808064; group id 410; item number 1012; lccId None; manufacturer id BQU Source form: Tab; strength: 5mg & 325mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916475 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15514
Interchangeable products
Apo-Oxycodone/Acet · DIN 02324628 · $0.1285 Endocet · DIN 01916548 · $0.1285 Sandoz Oxycodone/Acetaminophen · DIN 02307898 · $0.1285 Teva-Oxycocet · DIN 00608165 · $0.1285
Shortage status: discontinued (2017-07-21, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916475
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-08-23 — choose a marketed DIN from the same-category list.

OXYCODONE HCL & ACETYLSALICYLIC ACID

1 general benefit · 1 not a benefit

Other products in the same Health Canada class (N02A, N02AA) — coverage varies; not interchangeable

  • Hydromorphone (Hydromorph Contin): general benefit, Not a benefit
  • Morphine (M-Eslon): general benefit, Not a benefit
  • Acetylsalicylic acid + butalbital + caffeine + codeine (Fiorinal C1/4): not a benefit
  • Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, Not a benefit
  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, Not a benefit
  • Fentanyl transdermal system (Duragesic 12): limited Use 511, Limited Use 689, Not a benefit

2 more in the class list below

Ratio-Oxycodan · DIN 00608157 · 5mg & 325mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ratio-Oxycodan · DIN 00608157 Manufacturer: Ratiopharm Inc.; listing date 1996-10-01 Health Canada: Marketed since 2017-12-21 · brand TEVA-OXYCODAN · ATC N02AJ18 OXYCODONE AND ACETYLSALICYLIC ACID, N02AJ18 OXYCODONE AND ACETYLSALICYLIC ACID · form Tablet · route Oral · ingredients OXYCODONE HYDROCHLORIDE 5 MG, ACETYLSALICYLIC ACID 325 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Ratio-Oxycodan: Formulary list price $0.4599/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4599 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5777 · Verify on the e-Formulary ↗ (DIN 00608157)

Source record
DIN 00608157: Ratio-Oxycodan Raw flags: sec3=Y Item: 280808065; group id 411; item number 1013; lccId None; manufacturer id RPH Source form: Tab; strength: 5mg & 325mg Recorded listing: General benefit Source prices (unrounded): $0.4599; ministry $0.4599 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00608157 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5777
Interchangeable products
Percodan · DIN 01916572 · not recorded
Shortage status: resolved shortage (ended 2026-02-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00608157
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Percodan · DIN 01916572 · 5mg & 325mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-06-26 — choose a marketed DIN from the same-category list.Discontinued 2009-06-26 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-06-26 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-06-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Percodan · DIN 01916572 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2008-12-23 Health Canada: Cancelled post market since 2009-06-26 · brand PERCODAN · ATC N02AJ18 OXYCODONE AND ACETYLSALICYLIC ACID, N02AJ18 OXYCODONE AND ACETYLSALICYLIC ACID · form Tablet · route Oral · ingredients ACETYLSALICYLIC ACID 325 MG, OXYCODONE HYDROCHLORIDE 5 MG · company Bristol-myers squibb canada · schedule Narcotics (cdsa i)
Check this DIN again · Health Canada product record

Percodan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15513 · Verify on the e-Formulary ↗ (DIN 01916572)

Source record
DIN 01916572: Percodan Raw flags: notABenefit=Y, sec3=Y Item: 280808065; group id 411; item number 1013; lccId None; manufacturer id BQU Source form: Tab; strength: 5mg & 325mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01916572 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15513
Interchangeable products
Ratio-Oxycodan · DIN 00608157 · $0.4599
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916572
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-06-26 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE 28:08:08 Opiate Agonists

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 300mg & 15mg & 15mg, 300mg & 15mg & 30mg · Tab

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab

TRAMADOL HCL & ACETAMINOPHEN

· 11 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab

CODEINE SULFATE TRIHYDRATE & MONOHYDRATE

· 4 products · Limited Use, codes 201 · strengths: 50mg, 100mg, 150mg, 200mg · CR Tab

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:08:08
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: moderately pain, pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE · General benefit (2), Listed, not a benefit (2) INDICATIONS AND CLINICAL USE Adults TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain. PM: https://pdf.hres.ca/dpd_pm/00065848.PDF; date July 15, 2014; DIN 00653241; fetched 2026-09-10 Product monograph BUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Adults BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for: • the relief of moderate to severe acute pain. PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10 Product monograph CELECOXIB · Limited Use, codes 316, 317 1 INDICATIONS CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with: • Osteoarthritis, • Adult Rheumatoid Arthritis, and • Ankylosing Spondylitis CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain in adults in conditions such as the following: • Musculoskeletal and/or soft tissue trauma including sprains, • Postoperative orthopaedic, and • Pain following dental extraction CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic events), which can be fatal. PM: https://pdf.hres.ca/dpd_pm/00080998.PDF; date 2025-07-09; DIN 02239941; fetched 2026-09-10 Product monograph CODEINE SULFATE TRIHYDRATE & MONOHYDRATE · Limited Use, codes 201 1 Indications CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. PM: https://pdf.hres.ca/dpd_pm/00078791.PDF; date 2025-03-04; DIN 02163748; fetched 2026-09-10 Product monograph HYDROMORPHONE HCL · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) 1 INDICATIONS DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in adults. 1.1 Pediatrics No data are available to Health Canada. PM: https://pdf.hres.ca/dpd_pm/00072218.PDF; date August 29, 2023; DIN 00125083; fetched 2026-09-10 Product monograph TRAMADOL HCL & ACETAMINOPHEN · Off-Formulary Interchangeable, not an ODB benefit INDICATIONS AND CLINICAL USE Adults: APO-TRAMADOL/ACET (tramadol hydrochloride and acetaminophen) is indicated for the management of moderate to moderately severe pain. PM: https://pdf.hres.ca/dpd_pm/00067347.PDF; date September 14, 2022; DIN 02336790; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. Supeudol® 5 / Supeudol® 10 is not indicated as an as-needed (prn) analgesic. 1.1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of oxycodone hydrochloride has not been studied in the pediatric population. Therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range and titrated slowly, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy (see 4 DOSAGE AND ADMINISTRATION and 10.3 Pharmacokinetics, Special Populations and Conditions, Geriatrics). https://pdf.hres.ca/dpd_pm/00080231.PDF PM date: not printed or not captured Source product: SUPEUDOL 10; DIN 00443948; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults TEVA-OXYCOCET (oxycodone hydrochloride and acetaminophen) is indicated for the relief of moderate to moderately severe pain, including conditions accompanied by fever. TEVA-OXYCOCET is not indicated as an as-needed (prn) analgesic. Geriatrics (> 65 years of age) In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Geriatrics). Pediatrics (< 18 years of age) The safety and efficacy of TEVA-OXYCOCET has not been studied in the pediatric population. Therefore the use of TEVA-OXYCOCET is not recommended in patients under 18 years of age. https://pdf.hres.ca/dpd_pm/00047061.PDF PM date: August 22, 2018 Source product: TEVA-OXYCOCET; DIN 00608165; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS Adults TEVA-OXYCODAN (oxycodone hydrochloride and acetylsalicylic acid (ASA)) is indicated for: • the relief of mild to moderately severe pain, including conditions accompanied by fever and/or inflammation. TEVA-OXYCODAN is not indicated as an as-needed (prn) analgesic. 1.1 Pediatrics (< 18 years of age) The safety and efficacy of TEVA-OXYCODAN has not been studied in the pediatric population. Therefore Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics (> 65 years of age) In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy (see 10 CLINICAL, Special Populations and Conditions, Geriatrics). https://pdf.hres.ca/dpd_pm/00075881.PDF PM date: May 22, 2024 Source product: TEVA-OXYCODAN; DIN 00608157; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Oxycodone/Acet · DIN 02324628 Shortage status: shortage reported ended 2026-06-18 (report last updated 2026-06-18); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02324628

Check this DIN again

Teva-Oxycocet · DIN 00608165 Shortage status: active shortage (reported 2025-06-18, estimated to end 2026-10-01, last updated 2026-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00608165

Check this DIN again

Sandoz Oxycodone/Acetaminophen · DIN 02307898 Shortage status: discontinued (2024-05-01, reported by SANDOZ CANADA INCORPORATED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02307898

Check this DIN again

Endocet · DIN 01916548 Shortage status: discontinued (2017-09-21, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916548

Check this DIN again

Percocet · DIN 01916475 Shortage status: discontinued (2017-07-21, reported by BRISTOL-MYERS SQUIBB CANADA); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916475

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Oxycodone (Supeudol)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For use when palliative patient cannot use combination oxycodone and acetaminophen.

Ministry criteria corpus 2025-01-01; page 474

Oxycodone Brand(s): Supeudol DOSAGE FORM/ STRENGTH:5 mg, 10 mg, 20 mg
For use when palliative patient cannot use combination oxycodone and acetaminophen.
Standard Approval Duration: 12 months

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Other review policies

For Oxy.IR, PMS-Oxycodone, Percocet, Percodan: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026